Search

Displaying results 3691 - 3700 of 8010 in total
  1. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).

  2. Drug

    Apronalide

    go.drugbank.com/drugs/DB13221
    Approved

    Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].

  3. Drug

    Dihydroquinidine barbiturate

    go.drugbank.com/drugs/DB01341
    Experimental

  4. Drug

    Lercanidipine

    go.drugbank.com/drugs/DB00528
    ApprovedInvestigationalWithdrawn

    Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

  5. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    It differs from TCAs in that it does not appear to block serotonin reuptake.

    Categories: Antidepressive Agents Indicated for Depression
  6. Drug

    Bimoclomol

    go.drugbank.com/drugs/DB06258
    Experimental

    Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

  7. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  8. Drug

    Lonaprisan

    go.drugbank.com/drugs/DB16221
    Investigational

    Lonaprisan is under investigation in clinical trial NCT00555919 (ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer).

  9. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.

  10. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … 12 years and older to be approved by the FDA.